Ophthalmology & Visual Sciences at the Eye Institute

Ophthalmology and Visual Sciences

Currently Enrolling Study

Novartis RAVEN Study for Central Retinal Vein Occlusion (CRVO)

Purpose of study:
This research study is being done to see how safe and effective a drug called brolucizumab is in treating macular swelling (or edema) caused by central retinal vein occlusion, or CRVO. Brolucizumab will be compared to a drug called Eylea®, or aflibercept; Eylea® is already FDA-approved for treatment of swelling caused by CRVO, while brolucizumab is still being studied. This study will help determine whether brolucizumab is safe and effective in treating CRVO. 

What is Central Retinal Vein Occlusion (CRVO)?
Central Retinal Vein Occlusion (CRVO) is a disease that blurs the sharp, central vision you need for "straight-ahead" activities such as reading, sewing, and driving. The retina is the thin tissue at the back of the eye that contains light-sensitive cells that allow you to see. CRVO occurs when the main vein in your retina becomes blocked and leaks, causing swelling in the central part of your retina. This swelling is what may cause you to lose vision in the eye, and your vision may continue to worsen if the swelling is left untreated. 

What is involved?
The study will last about 18 months with up to 21 study visits at the Eye Institute. You will be randomly assigned to receive either brolucizumab or Eylea®, and you will have an equal chance of receiving either drug. You will not be told which group you have been assigned to.

Compensation:
Research volunteers will receive $75 for each study visit that they complete.

You may be eligible to participate in this study if you meet these criteria.

1. An eye doctor has told you that you have macular edema (swelling) due to CRVO or you have been diagnosed with macular edema (swelling) due to CRVO  < 6 months ago (will be confirmed by a study doctor).
2. You are 18 years of age or older.
3. You have not previously received any injection treatments or investigational drugs in the study eye.
4. You have not received a steroid injection in the study eye.
5. You have not had eye surgery in the study eye in the last 3 months.
6. You have not had a stroke or heart attack in the last 6 months.
 

More Information:
 
Contact Katie McKenney with questions. (414) 955-7866 or email

IRB ####  approved MM/DD/YYYY


Contact Ophthalmology

For patient care inquires, call us at (414) 955-2020 or use MyChart. Email is for research and education inquiries only.

Eye Institute Location

925 N. 87th St.

Milwaukee, WI 53226

 

Appointments

(414) 955-2020

(414) 955-6166 (fax)

 

Continuing Medical Education

Mary Schafer

mschafer@mcw.edu

(414) 955-7840

 

Medical Education Coordinator

Leslie Bencivenga

lbencive@mcw.edu

Refer to Us - Consultation requests

Physician Referral Form (PDF)

Fax to (414) 955-0136

 

Emergent Requests

Within 48 hours call

(414) 955-2020

 

Clinical Research

Vesper Williams

vewilliams@mcw.edu

(414) 955-7862

 

Advanced Ocular Imaging Program

aoip@mcw.edu

(414) 955-2647

Eye Institute Google map location